Newsroom

Industry News

3 Mar

ImmunoCellular Therapeutics to Present at ROTH Conference on March 11th

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 5:00 pm PT, at the Ritz-Carlton Hotel, Laguna Niguel, CA. To access...

Read more

25 Feb

ImmunoCellular Therapeutics (IMUC) Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access...

Read more

18 Feb

Intellipharmaceutics (IPCI) Announces 2013 Year End Results

Significant Year Sees Commercial Launch of Generic Focalin XR(R) Intellipharmaceutics International Inc. (IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2013. All...

Read more

3 Feb

Intellipharmaceutics (IPCI) Receives $3.1 Million From Par Pharmaceuticals, Inc.

Intellipharmaceutics International Inc. (IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the receipt of approximately $3.1 million as its first payment relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by its...

Read more

13 Jan

SeeThruEquity Initiates Research Coverage on AtheroNova, Inc. (AHRO)

AtheroNova, Inc. : SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on AtheroNova, Inc. (OTCQB: AHRO), a biotechnology company focused on the discovery, research, development and licensing of novel...

Read more

19 Sep

AtheroNova (AHRO) to Present at the 2013 Aegis Healthcare Conference in Las Vegas

AtheroNova Inc. (AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Chairman and CEO, Thomas W. Gardner, will present a corporate overview at the 2013 Aegis Capital Healthcare Conference. The presentation will...

Read more

Page 234 of 234« First...102030...230231232233234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address